Search - tctmd.com

Displaying 1 - 20 of 86

Sort: Relevancy | Date

News Daily News

More A-fib, No Drop in Stroke or Death With Surgical Left Atrial Appendage Exclusion

Todd Neale

December 05, 2016

News Opinion Editor's Corner TCT 2016

My Takeaways From TCT 2016: Surprises, Presuppositions, and the Gift of the Giveaway

Shelley Wood

November 07, 2016

News Conference News

Watchman, Amulet LAA Closure Devices Carry Low Complication Rates

Todd Neale

November 04, 2016

News Industry News

Initial Results of LAA Closure Device for Stroke Prevention in Patients with Atrial Fibrillation Demonstrate Device Safety and Low Rates of Major Adverse Events

November 02, 2016

Presentation TCT 2016

Management of Residual Leaks After LAA Closure

Presenter: David R. Holmes Jr., Jacqueline Saw

November 01, 2016

Presentation TCT 2016

Assessment and Implications of Residual Leaks After Percutaneous and Surgical LAA Closure

Presenter: David R. Holmes Jr., Jacqueline Saw

November 01, 2016

Presentation TCT 2016

Reimbursement Challenges For LAAC: Balancing The Clinical Need Vs. Robust Data Vs. Societal Economic Considerations

Presenter: Aaron V. Kaplan, Rachel Neubrander, Tamara Syrek Jensen

November 01, 2016

Presentation TCT 2016

Follow-up Evaluation After LAA Closure

Presenter: David R. Holmes Jr., Jacqueline Saw, Bushra S Rana

November 01, 2016

Presentation TCT 2016

Pivotal Trial Design Considerations: Noninferiority vs Superiority, Device, Control Arm Anticoagulation Durations, NOAC Considerations and More Industry and Clinician Perspectives

Presenter: Aaron V. Kaplan, Rachel Neubrander, Brian K. Whisenant

November 01, 2016

Presentation TCT 2016

Is Ablation an Alternative to Triple Therapy in Patients With Atrial Fibrillation and PCI or ACS?

Presenter: Martin W. Bergmann, Samir R. Kapadia, Vivek Y. Reddy

November 01, 2016

Presentation TCT 2016

Trial Designs For LAA Closure: Potential Regulatory Pathways and Unanswered Questions What FDA Would Like to See

Presenter: Aaron V. Kaplan, Rachel Neubrander, Katherine Wallon

November 01, 2016

Presentation TCT 2016

Should the New Oral Anticoagulants (vs Warfarin) Change the Equation of Triple Therapy vs LAA Closure?

Presenter: Martin W. Bergmann, Samir R. Kapadia, Harvey D. White

November 01, 2016

Presentation TCT 2016

Selecting the Right LAA Closure Device Based on Patient Characteristics and LAA Anatomy: Occluder, Ligation, or Clipping

Presenter: Martin W. Bergmann, Samir R. Kapadia, Jason H. Rogers

November 01, 2016

Presentation TCT 2016

Special Tips and Tricks for LAA Closure Using the Lariat

Presenter: Krzysztof Bartus, Randall J. Lee

November 01, 2016

Presentation TCT 2016

Special Tips and Tricks for LAA Closure Using the Lifetech LAA Occluder

Presenter: Krzysztof Bartus, Yat-Yin Lam

November 01, 2016

Presentation TCT 2016

Is LAA Closure an Alternative to Triple Therapy for all Patients or Those at High Bleeding Risk? Current Dataset

Presenter: Martin W. Bergmann, Samir R. Kapadia, Brian K. Whisenant

November 01, 2016

Presentation TCT 2016

Special Tips and Tricks for LAA Closure Using the Cardia LAA Occluder

Presenter: Krzysztof Bartus, Josep Rodés-Cabau

November 01, 2016

Presentation TCT 2016

Why Triple Therapy? Rationale and Potential Role for LAA Closure in the PCI Patient

Presenter: Martin W. Bergmann, Samir R. Kapadia, Ashish Pershad

November 01, 2016

Presentation TCT 2016

Special Tips and Tricks for LAA Closure Using the Occlutech LAA Occluder

Presenter: Krzysztof Bartus, Eustaquio Maria Onorato

November 01, 2016

Presentation TCT 2016

Special Tips and Tricks for LAA Closure Using the WaveCrest LAA Occluder

Presenter: Krzysztof Bartus, Vivek Y. Reddy

November 01, 2016

Advertisement

More A-fib, No Drop in Stroke or Death With Surgical Left Atrial Appendage Exclusion

My Takeaways From TCT 2016: Surprises, Presuppositions, and the Gift of the Giveaway

Watchman, Amulet LAA Closure Devices Carry Low Complication Rates

Initial Results of LAA Closure Device for Stroke Prevention in Patients with Atrial Fibrillation Demonstrate Device Safety and Low Rates of Major Adverse Events

Management of Residual Leaks After LAA Closure

Assessment and Implications of Residual Leaks After Percutaneous and Surgical LAA Closure

Reimbursement Challenges For LAAC: Balancing The Clinical Need Vs. Robust Data Vs. Societal Economic Considerations

Follow-up Evaluation After LAA Closure

Pivotal Trial Design Considerations: Noninferiority vs Superiority, Device, Control Arm Anticoagulation Durations, NOAC Considerations and More Industry and Clinician Perspectives

Is Ablation an Alternative to Triple Therapy in Patients With Atrial Fibrillation and PCI or ACS?

Trial Designs For LAA Closure: Potential Regulatory Pathways and Unanswered Questions What FDA Would Like to See

Should the New Oral Anticoagulants (vs Warfarin) Change the Equation of Triple Therapy vs LAA Closure?

Selecting the Right LAA Closure Device Based on Patient Characteristics and LAA Anatomy: Occluder, Ligation, or Clipping

Special Tips and Tricks for LAA Closure Using the Lariat

Special Tips and Tricks for LAA Closure Using the Lifetech LAA Occluder

Is LAA Closure an Alternative to Triple Therapy for all Patients or Those at High Bleeding Risk? Current Dataset

Special Tips and Tricks for LAA Closure Using the Cardia LAA Occluder

Why Triple Therapy? Rationale and Potential Role for LAA Closure in the PCI Patient

Special Tips and Tricks for LAA Closure Using the Occlutech LAA Occluder

Special Tips and Tricks for LAA Closure Using the WaveCrest LAA Occluder

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content